Izumi Tohru
Nihon Rinsho. 2014 Jun;72(6):1089-93.
Recently, new agents have explored in the treatment of multiple myeloma (MM), according to the identification of the novel pathogenetic mechanisms. Proteasome inhibitor (bortezomib) and immunomodulatory drugs (thalidomide and lenalidomide) now play important roles in the treatment of MM, and they have resulted in an improvement of the outcome of the patients. However, MM remains incurable and the prognosis is very poor in the patients who become refractory to bortezomib and IMiDs. New agents with novel mechanism of action in MM (monoclonal antibodies, deacetylase inhibitors, and so on) will be discussed in this review.
近年来，根据新发现的发病机制，新型药物已被用于探索多发性骨髓瘤（MM）的治疗。蛋白酶体抑制剂（硼替佐米）和免疫调节药物（沙利度胺和来那度胺）目前在MM治疗中发挥着重要作用，它们改善了患者的治疗效果。然而，MM仍然无法治愈，对于硼替佐米和免疫调节药物难治的患者预后很差。本文将讨论在MM中具有新作用机制的新型药物（单克隆抗体、脱乙酰酶抑制剂等）。
